<span item_type="fundamental" item_id="32493b66009434911a928512c97b2c3a" counter_id="ST/US/ENGNW" env="prod"></span><span item_type="announcement" item_id="559589439481644545" env="prod"></span><p>EPS: As of FY2025 Q3, the actual value is USD 0.57.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -28.75 M.</p><p></p><h3>Operating Expenses</h3><ul><li>Total operating expenses for the three months ended July 31, 2025, were $29.9 million, compared to $16.8 million for the same period in 2024. This increase was primarily due to a rise in research and development expenses by $11.0 million, driven by manufacturing and clinical costs related to the LEGEND study and personnel-related costs. General and administrative expenses also increased by $2.2 million, mainly due to personnel-related expenses and professional services.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000095017025114220/engn-ex99_1.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss attributable to common shareholders for the three months ended July 31, 2025, was approximately $28.9 million, or $0.57 per share, compared to approximately $14.1 million, or $0.32 per share, for the same period in 2024. The increase in net loss is mainly attributed to the rise in operating expenses, partially offset by net interest income.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000095017025114220/engn-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>As of July 31, 2025, cash, cash equivalents, and marketable securities were $224.9 million. The company expects these funds to cover operating expenses, debt obligations, and capital expenditures into 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000095017025114220/engn-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>enGene plans to provide an update on the LEGEND trial’s pivotal cohort data in the fourth quarter of 2025 and anticipates filing a Biologic License Application (BLA) for the LEGEND pivotal cohort in the second half of 2026. The company expects its cash and marketable securities to fund operations into 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000095017025114220/engn-ex99_1.htm"></span></li></ul>

ENGENE HOLDINGS INC C/WTS 31/10/2028 (TO PUR COM) CL A | 8-K: FY2025 Q3 EPS: USD 0.57